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Abstract 
Motivation. Three–dimensional structures of pharmacologically important macromolecules offer a route to the 
discovery of new drugs. Understanding the macromolecule–ligand interactions and validation of method used for 
docking and virtual screening of chemical databases is crucial step in structure–based design. We carried out 
molecular docking for a set of eighty two structurally diverse COX–1/COX–2 inhibitors including traditional 
NSAIDs and the recently developed coxibs such as celecoxib, rofecoxib, valdecoxib and etoricoxib using FlexX 
method to find out how good this method differentiate between the active and inactive compounds. 
Method. FlexX is one of the fast flexible docking method that uses an incremental construction algorithm to 
place ligands into an active site. The scoring function (empirical binding free energy) of the FlexX used to 
estimate the free binding energy of the protein–ligand complex is called F_score. 
Results. Reproducibility of the experimental conformations of the bound ligands such as SC–558, indomethacin, 
and flurbiprofen indicates the better performance of FlexX method. Good correlation between the standard 
FlexX score (F_score) and the COX–2 inhibitory activity (pIC50) was observed. Simple linear regression analysis 
provided the correlation coefficient values of 0.731 and 0.670 for two classes of COX–2 inhibitors. 
Conclusions. Flexible docking of eighty two structurally diverse COX–2 inhibitors has been successfully carried 
out. Some false positives and false negatives were observed but considering the limitations of the available 
docking programs, the results are encouraging. The in depth analysis of the resulted COX–2–ligand complexes 
may improve our knowledge in understanding the binding interactions in detail. Thus, this study will be useful 
for the design of novel COX–2 inhibitors based on docking and the resulted bioactive conformations of the 
ligands will be useful in building structure–based 3–D QSAR model. 
Keywords. FlexX; cyclooxygenase–2; docking; structure–based drug design; NSAIDs. 
1 INTRODUCTION 
The process of structure–based design started with the detailed analysis of binding site of the 
target protein, preferably in its complex form with a ligand. The knowledge of binding site helps to 
design novel drug candidates with better potency. Another approach that uses the structural 
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information deals with the protein–based virtual screening of chemical databases wherein prior to 
biological screening, the potent compounds are computationally figured out from a large chemical 
library. Docking methods have the added advantage compared to 2–D similarity and 3–D 
pharmacophore search methods because it makes use of 3–D receptor structure in a quantitative 
way. Compound selection based on docking calculations alone and or combined with virtual 
screening has been carried out for various targets such as thrombin [1], thymidylate synthase [2], 
dihydrofolate reductase [3], HIV protease [4], PTP1B [5], and human carbonic anhydrase [6]. Such 
study led to the identification of novel compounds with the potency between 1–100µM. 
COX–2 is one of the well–known targets for the anti–inflammatory therapy. Selective inhibition 
of this enzyme overcomes the side effects associated with the traditional NSAIDs. The reported 3–
D QSAR models [7–10] are mainly focused to a particular class of compounds and such models 
may not be useful to predict structurally diverse compounds. Stewart et al. [11] have reported a 
novel lead, phenothiazine for the inhibition COX–2 enzyme using combined 3–D database 
searching and combinatorial chemistry methodologies. The availability of several crystal structures 
of complexes of COX–2 with the inhibitors provides the possibility to apply structure–based design 
techniques for the development of specific and potent inhibitors. Therefore, we thought of 
exploiting the structure–based approach to design novel COX–2 inhibitors by docking studies 
combined with visualization of active site–ligand interactions. 
2 MATERIALS AND METHODS 
Table 1. Selected residues within 4 Å distance from SC–558 
S.No. Aminoacid Number 
1 Arg 120 
2 Leu 352 
3 Ala 527 
4 Gly 526 
5 Val 523 
6 Val 349 
7 Leu 359 
8 His 90 
9 Tyr 355 
10 Ser 353 
11 Arg 513 
12 Phe 518 
13 Ile 517 
14 Ala 516 
15 Gln 192 
16 Tyr 385 
17 Trp 387 
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Figure 1. Structures of compounds (including NSAIDs) selected for docking studies. 
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Table 2. Structures of compounds (1,2–diaryl heterocyclic class) selected for docking studies 
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No Ring R1 R2 No Ring R1 R2
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Table 2. (Continued) 
No Ring R1 R2 No Ring R1 R2
30
N
N
S CH3
CH3 3,4–di–F–C6H3 46 N O
O
NH2 3–COOH– C6H4
31 N O
O
NH2 4–CF3–C6H4 47 O
O
CH3 C6H5
32 N O
O
NH2 c–C6H11 48b
O
N
CH3
NH2 c–C6H11
a SO2R1 replaced by SCH3
b 3–H of the sulphonyl phenyl ring is substituted by F 
Table 3. Structures of 1,3–diaryl heterocyclic compounds 
N
R R2R1
No Ring R R1 R2 No Ring R R1 R2
49 H H H 66 H F F 
50 H H H 67 N H H H 
51 CH3 H H 68
HN
H H H 
52 NH2 H H 69 H H H 
53 NHMs H H 70 H F F 
54 CH2COOH H H 71 H F F 
55 H F F 72 H F CH3SO2
56 H CH3S CH3S 73 H CH3SO2 CH3SO2
57 H CH3 CH3 74 H H H 
58 H OCH3 OCH3 75 H F F 
59 H Cl Cl 76 H H H 
60 H F Imidazol–1–yl 77 H 4–F 3–NHAc 
4–F 
3–NHAc 
61 H Imidazol–1–yl Imidazol–1–yl 78 H 4–F 3–NHCH3
4–F 
3–NHCH3
62 H H H 79a H – – 
63 H H H 80
N
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Table 3. (Continued) 
No Ring R R1 R2 No Ring 
64 CH3 H H 81
S
65 H H H 82
N
a replacement of phenyl with pyridine 
Table 4. Compounds assayed by human whole blood method, COX–2 potency and FlexX docking scores 
Entry Compound IC50 (µM) COX–2 pIC50 COX–2 FlexX Score 
Class 1 Highly potent molecules (IC50?1.0µM) 
1 Diclofenac (1) 0.05 7.30 –25.80 
2 Indomethacin (2) 0.46 6.34 –20.50 
3 Ketorolac (3) 0.86 6.06 –28.70 
4 Meloxicam (4) 0.7 6.12 –20.20 
5 Flosulide (5) 0.7 6.12 –21.60 
6 NS–398 (6) 0.47 6.33 –10.60 
7 Dup–697 (17) 0.06 7.22 –20.30 
8 Celecoxib (18) 1.0 6.00 –24.10 
9 Rofecoxib (19) 0.5 6.30 –21.60 
10 Valdecoxib (20) 0.89  6.05 –24.87 
11 Etoricoxib (21) 1.0 6.00 –14.68 
12 22 0.19 6.72 –22.92 
13 23 0.03 7.52 –14.50 
14 24 0.08 7.10 –28.54 
15 25 0.40 6.40 –28.10 
16 60 0.08 7.10 –12.20 
17 75 0.12 6.92 –12.88 
Class II Moderately potent molecules (IC50>1–30µM) 
18 26 9.08 5.01 –13.90 
19 27 5.2 5.28 –9.88 
20 28 13.4 4.87 –14.14 
21 29 2.2 5.66 –17.56 
22 30 17.5 4.76 –13.25 
23 Tenoxicam (7) 14.22 4.85 –19.67 
24 Sulidac sulphide (8) 10.43 4.98 –11.77 
25 L–745337 (9) 9.7 5.01 –13.58 
26 31 2.0 5.70 –28.00 
27 32 18.9 4.72 –16.20 
28 33 4.7 5.33 –22.90 
29 Flurbiprofen (10) 6.46 5.19 –25.70 
30 Piroxicam (11) 8.99 5.05 –20.00 
31 Tolmetin (12) 7.09 5.15 –19.10 
32 Ketoprofen (13) 1.08 5.97 –26.80 
Class III Inactive molecules ((IC50>30µM)
33 Ibuprofen (14) >30 4.52 –8.84 
34 Phenylbutazone (15) >30 4.52 –12.15 
35 Naproxen (16) 73.74 4.13 –19.65 
36 34 >33 4.48 –16.01 
37 35 >33 4.48 –23.65 
38 36 >33 4.48 –15.47 
39 37 >33 4.48 –13.20 
40 38 >33 4.48 –11.97 
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Table 4. (Continued) 
Entry Compound IC50 (µM) COX–2 pIC50 COX–2 FlexX Score 
41 39 >33 4.48 –6.85 
42 40 >33 4.48 –15.29 
43 41 >33 4.48 –13.41 
44 42 >30 4.48 –15.62 
45 43 >30 4.48 –13.53 
46 44 >33 4.48 –15.20 
47 45 59%a 4.00 –31.00 
48 46 100 4.00 –32.00 
49 47 Inactive – –23.25 
50 JTE–522 (48) >33 4.48 –19.68 
a at 100µM 
Table 5. Compounds assayed by mouse macrophage method, COX–2 potency and FlexX docking scores 
Entry Compound IC50 (nM) COX–2 pIC50 COX–2 FlexX Score 
51 49 1.5 8.82 –27.20 
52 50 3.3 8.48 –24.80 
53 51 >1000 6.00 –21.40 
54 52 1.8 8.74 –20.30 
55 53 500 6.30 –12.10 
56 54 >100 7.00 –18.20 
57 55 1.7 8.77 –27.20 
58 56 500 6.30 –11.20 
59 57 16.7 7.78 –12.00 
60 58 21.3 7.67 –16.40 
61 59 5.0 8.30 –21.00 
62 60 42.0 7.38 –17.20 
63 61 >100 7.00 –20.30 
64 62 3.1 8.51 –27.50 
65 63 14.5 7.84 –22.10 
66 64 >1000 6.00 –5.90 
67 65 0.7 9.15 –27.50 
68 66 2.9 8.54 –26.00 
69 67 >100 7.00 –11.10 
70 68 >100 7.00 –16.70 
71 69 2.6 8.58 –15.70 
72 71 4.5 8.35 –18.80 
73 72 700 6.15 –15.10 
74 73 >10000 5.00 –14.50 
75 74 1.6 8.79 –11.50 
76 76 35.6 7.45 –14.50 
77 77 >100 7.00 –30.70 
78 78 >100 7.00 –19.60 
79 79 >100 7.00 –17.80 
80 80 50.0 7.30 –25.90 
81 81 10.9 7.96 –16.20 
82 82 28.7 7.54 –13.50 
2.1 Ligand Preparation 
All the molecular modeling and docking studies were performed on a Silicon Graphics Octane 2 
workstations using Sybyl6.8 [12]. Eighty two compounds (Figure 1, Tables 2 and 3) were selected 
based on structural diversity and wide range of biological activity [13–24]. Major COX–2 inhibitory 
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data was obtained from the human whole blood method [13] developed by Merck Frost Center. 
Known ligands were extracted from the PDB file and converted into SYBYL mol2 format. 
Hydrogens were added and atom and bond types were corrected. Other molecules were sketched 
and subjected to systematic conformational search to find out the possible lowest energy 
conformation. The charges were calculated using Gasteiger–Hückel method. The ligands were 
energy minimized using the Tripos force field. Compounds 49–82 used for CoMFA model [10] 
were submitted for docking. The compounds having carboxylic acids were treated as carboxylate 
and the formal charges were supplied. 
2.2 Receptor File (rdf) Preparation 
The coordinates of cyclooxygenase–2 enzyme crystal structure (1CX2) were retrieved from the 
PDB. The residues (Table 1) within 4 Å distance from SC–558 [25] were selected manually. After 
the selection, a radius of 2.5 Å was specified in order to extent the binding site. 
2.3 Molecular Docking
2.3.1 Details of FlexX
The physicochemical model behind FlexX [26] can be divided into three parts: the 
conformational space of the ligand, the model of protein–ligand interactions, and the scoring 
function. To each acyclic single bond, a set of low–energy torsion angles is assigned using the 
MIMUMBA torsion angle database. Generated conformations are only tested for intramolecular 
clashes, and there is no conformational energy term in the scoring function. The scoring function 
[27] of FlexX is the function developed by Böhm for the de novo design program LUDI with some 
minor changes. 
?G = ?G0 + ?grot x Nrot (1)
+ ?Ghb ? f(?R, ??) neutral H–bonds (2)
+ ?Gio ? f(?R, ??) ionic interactions (3)
+ ?Garo ? f(?R??) aromatic interactions (4)
+ ?Glipo? f(?R) lipohilic contributions (5)
The scoring function can be divided into three parts. The first part (1) consists of a fixed term 
?G0 and a term ?grot×Nrot taking into account the loss of entropy during ligand binding. The second 
part (2–4) contains the contributions for matched interaction groups like hydrogen bonds, salt 
bridges and charged hydrogen bonds and aromatic interactions. Each of these terms consists of a 
fixed contribution per interaction multiplied by a penalty function f(?R, ??). The penalty functions 
are piecewise linear functions scaling the contribution of an interaction with respect to its geometry. 
The third part (5) rates the atom–atom contacts between protein and ligand such as hydrophobic 
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contacts and forbiddingly close contacts (clashes). The second and third parts of the scoring 
function are called match score and contact score, respectively. 
The selected compounds were docked into the COX–2 active site using the default FlexX 
parameter settings. The results of top ranked scoring conformation were analyzed and used in the 
correlation of COX–2 inhibitory activity. 
Molecules from human whole blood assay Molecules from mouse macrophage assay 
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Figure 2. FlexX score vs COX–2 Inhibitory Activity (pIC50).
Table 6. The rms deviation of known ligands 
S. No. Ligand PDB Enzyme RMSD (Å) 
1 SC–558 1CX2 COX–2 1.062 
2 Flurbiprofen 3PGH COX–2 1.524 
3a Indomethacin 4COX COX–2 0.799 
a Subcore pocket (only 4Å distance residues from SC–558) was used 
3 RESULTS AND DISCUSSION 
Reproducibility of the experimental conformations of the bound ligands such as SC–558, 
indomethacin and flurbiprofen was observed from docking (Figures 8, 4, and 3). As previously 
observed by Plount–Price et al. [28] we found that FlexX docks the sulphonyl amino group of SC–
558 in a way that can make hydrogen bonding with Arg513 and His90. However in the crystal 
structure complex (1CX2.pdb) bad N–N contact was observed between sulphonyl amino group and 
nitrogen of His90. The carboxylate group of active NSAIDs was oriented towards the guanidine 
group of Arg120 (Figures 3–7). The top scoring docked conformation was selected and the non–
hydrogen atoms were aligned to the experimental conformation of the ligand. The low rms 
deviations (Table 6) between the theoretical and experimental conformations observed for the 
ligands studied indicated the better performance of FlexX method. 
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3.1 Compounds Tested by Human Whole Blood Assay 
The resulted FlexX scores and the COX–2 inhibitory activities were shown in Tables 4 and 5. 
We found more negative scores (Table 4) for the potent molecules, indicating the better binding of 
the ligands into the active site. Molecules NS–398 (6), etoricoxib (21), 23, 60 and 75 were found to 
be false negatives. AutoDock [29] method could successfully dock NS–398 into the active site of 
human COX–2. However, the docking scores were found to be less negative in case of moderately 
potent and inactive molecules. We observed some false positives (35, 45, 46, and 47) from the set 
of inactive molecules. FlexX assigned good scores to these inhibitors as these compounds form 
more than one hydrogen bond with the protein. These observations are in confirmatory with the 
virtual screening studies reported by Martin et al. [30]. The resulted FlexX docking score was 
correlated with the COX–2 inhibitory property (Figure 6). The linear regression analysis was 
performed for the molecules that are assayed by human whole blood method. After removing the 
false positives and false negatives the following regression equation was obtained for 40 molecules: 
COX–2 inhibitory activity (pIC50) = 3.181 – (0.114 × FlexX score). The r2 value was found to be 
0.534 and R–value was 0.731 with the standard error of 0.619. 
Figure 3. Binding of S–Flurbiprofen into the active site of COX–2 (stereoview). 
3.1.1 COX–2–Inhibitor Interactions 
Visualization of docked inhibitors in COX–2 enzyme reveals that the carboxylate group of 
NSAIDs is located in a favorable position to interact with the guanidinium group of Arg120 and OH 
of Tyr 355. Similar kind of orientations was observed from docking of NSAIDs using modeled 
human COX–2 enzyme by Autodock method by Pouplana et al. [29]. A bifurgated hydrogen bond 
between the carboxylate group of flurbiprofen and Arg120 was observed. Dock4.0 [31] docked 
flurbiprofen in similar orientation in the COX–2 active site. In case of ketorolac, ketoprofen and 
diclofenac, two hydrogen bonds were observed between the carboxylate oxygen atoms and OH, 
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guanidinium NH of Tyr355, Arg 120 respectively. The hydrogen bonding distances observed were 
3.02 Å (C=O…H–O–Tyr355) and 2.61Å (C–O…H–N–Arg120) in ketorolac–COX–2 complex. The 
phenyl ring of ketorolac was surrounded by the aromatic residues Phe518 and Trp387. The other 
part was oriented in the hydrophobic cleft formed by Val349, Leu531 and Ala527. The hydrogen 
bonding distances observed were 3.00 Å (C–O…H–O–Tyr355) and 2.91Å (C=O…H–N–Arg120) 
in ketoprofen–COX–2 complex. The methyl group of ketoprofen was oriented in a way to interact 
with hydrobhobic residues such as Leu531 and Ala527. 
Figure 4. Binding of indomethacin into the active site of COX–2 (stereoview). 
Figure 5. Binding of S–ketoprofen into the active site of COX–2 (stereoview). 
One of the phenyl rings was oriented in a way to make hydrophobic interaction with Leu352 and 
Ala527 and Val523. Another phenyl ring was surrounded by the aromatic residues Phe381 and 
Trp387. However, central carbonyl group of both ketorolac and ketoprofen was not involved in any 
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hydrogen bonding interactions with enzyme. 
Figure 6. Binding of Ketorolac into the active site of COX–2 (Stereoview). 
Figure 7. Binding of Diclofenac into the active site of COX–2 (stereoview). 
Figure 8. Binding of SC–558 into the active site of COX–2 (stereoview). 
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The conformation of diclofenac docked by FlexX method was quite different from the 
experimental conformation (1PXX.pdb). Molecule 49, a 1,3–diaryl analogue did not produce any 
hydrogen bonding interaction with the enzyme. Thus, the major interaction of this compound with 
enzyme is mainly hydrophobic. One of the phenyl rings was surrounded by the aromatic residues 
Tyr386, Trp387 and Phe518 of COX–2 active site. 
3.2 Compounds Tested By In vitro Mouse Macrophage Assay 
Another class of compounds selected for the docking studies is the non–sulphonyl analogues 
(Table 3). After removing the false positives (77, 80) and false negative (74) the following 
regression equation was obtained for 29 molecules of 1,3–diaryl isoindole (the binding orientation 
of the most active molecule 49 is shown Figure 9): COX–2 inhibitory activity (pIC50) = 5.233 – 
(0.119×FlexX score). The r2 value was found to be 0.449 and R–value was 0.670 with the standard 
error of 0.775. The calculated correlation coefficient values indicate a good correlation between the 
FlexX score and COX–2 inhibitory activity. 
Figure 9. Binding of 1,3–diaryl isoindole derivative (49) into the active site of COX–2 (stereoview). 
In general, from this exercise it was observed that the more negative is the score (more negative 
with respect to the value of –20) higher is the affinity of the ligands. Scores with more positive 
value compared to –20 was observed for moderate to low affinity ligands. Apart from this it was 
found that some compounds produced good scores and correlation with the pIC50 but were out of 
the actual active site and therefore before going for the selection of compounds for synthesis one 
should also visually monitor the interaction with the active site amino acid residues. Very recent 
report [32] showed that F_ score is better than other scoring functions such as PMF, D–score, G–
score and chemscore tried in the virtual screening of COX–2 inhibitors. Thus FlexX method is one 
of the best docking methods that can be used in designing novel COX–2 inhibitors. 
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4 CONCLUSIONS 
We have successfully carried out flexible docking for eighty two structurally diverse COX–2 
inhibitors. The obtained FlexX docking score was correlated with the biological activities. Some 
false positives and false negatives were observed but considering the limitations of the available 
docking program, the results are encouraging. The in depth analysis of the resulted COX–2–ligand 
complexes may improve our knowledge in understanding the binding interactions in detail. Thus 
this study will be useful for the design of novel COX–2 inhibitors based on docking and the resulted 
bioactive conformations of ligands will be useful in building structure–based 3–D QSAR model. 
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